Literature DB >> 14689582

Cholesterol and prostate cancer.

Michael R Freeman1, Keith R Solomon.   

Abstract

Cholesterol is a neutral lipid that accumulates in liquid-ordered, detergent-resistant membrane domains called lipid rafts. Lipid rafts serve as membrane platforms for signal transduction mechanisms that mediate cell growth, survival, and a variety of other processes relevant to cancer. A number of studies, going back many years, demonstrate that cholesterol accumulates in solid tumors and that cholesterol homeostasis breaks down in the prostate with aging and with the transition to the malignant state. This review summarizes the established links between cholesterol and prostate cancer (PCa), with a focus on how accumulation of cholesterol within the lipid raft component of the plasma membrane may stimulate signaling pathways that promote progression to hormone refractory disease. We propose that increases in cholesterol in prostate tumor cell membranes, resulting from increases in circulating levels or from dysregulation of endogenous synthesis, results in the coalescence of raft domains. This would have the effect of sequestering positive regulators of oncogenic signaling within rafts, while maintaining negative regulators in the liquid-disordered membrane fraction. This approach toward examining the function of lipid rafts in prostate cancer cells may provide insight into the role of circulating cholesterol in malignant growth and on the potential relationship between diet and aggressive disease. Large-scale characterization of proteins that localize to cholesterol-rich domains may help unveil signaling networks and pathways that will lead to identification of new biomarkers for disease progression and potentially to novel targets for therapeutic intervention. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14689582     DOI: 10.1002/jcb.10724

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  90 in total

1.  Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival.

Authors:  Erin L Richman; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci; June M Chan
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-19

Review 2.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

3.  Statins and prostate cancer diagnosis and grade in a veterans population.

Authors:  Wildon R Farwell; Leonard W D'Avolio; Richard E Scranton; Elizabeth V Lawler; J Michael Gaziano
Journal:  J Natl Cancer Inst       Date:  2011-04-15       Impact factor: 13.506

4.  Association of lipid metabolism with ovarian cancer.

Authors:  M Tania; M A Khan; Y Song
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

5.  Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.

Authors:  Xuan Chen; Yue Liu; Jian Wu; Huarong Huang; Zhiyun Du; Kun Zhang; Daiying Zhou; Kaylyn Hung; Susan Goodin; Xi Zheng
Journal:  Cancer Genomics Proteomics       Date:  2016 Mar-Apr       Impact factor: 4.069

6.  Membrane lipid profile alterations are associated with the metabolic adaptation of the Caco-2 cells to aglycemic nutritional condition.

Authors:  Vera F Monteiro-Cardoso; Amélia M Silva; Maria M Oliveira; Francisco Peixoto; Romeu A Videira
Journal:  J Bioenerg Biomembr       Date:  2014-02       Impact factor: 2.945

Review 7.  The effect of statins on cancer cells--review.

Authors:  Lucyna Matusewicz; Justyna Meissner; Monika Toporkiewicz; Aleksander F Sikorski
Journal:  Tumour Biol       Date:  2015-05-23

8.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

9.  Androgen deprivation by activating the liver X receptor.

Authors:  Jung Hoon Lee; Haibiao Gong; Shaheen Khadem; Yi Lu; Xiang Gao; Song Li; Jian Zhang; Wen Xie
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

10.  Seladin-1 expression is regulated by promoter methylation in adrenal cancer.

Authors:  Lisa Simi; Francesca Malentacchi; Paola Luciani; Stefania Gelmini; Cristiana Deledda; Rosaria Arvia; Massimo Mannelli; Alessandro Peri; Claudio Orlando
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.